Why the study?
Does the incidence of cough differ between ACE inhibitors and ARBs in pediatric patients with hypertension?
Does the incidence of cough differ between ACE inhibitors and ARBs in pediatric patients with hypertension?
The incidence of cough in pediatric patients treated with ACE inhibitors or ARBs for hypertension is low and similar between the two drug classes.
Cough incidence is similar with ACEis and ARBs in children; challenges adult-derived expectations and supports ACEi use in pediatrics.
The incidence of cough in children receiving antihypertension therapy with angiotensin-converting enzyme inhibitors (ACEis) or angiotensin receptor blockers (ARBs) is unknown. We analyzed patient-level data from eight randomized trials for the treatment of pediatric hypertension, six of them involving ACEis and two involving ARBs. The incidence of cough in children receiving ACEis (reported cough, 3.2%) was similar to that in children receiving ARBs (reported cough, 1.8%) (P = 0.34). Reports of cough were lower in children than in adults.
No takes yet. Share an insight, caveat, or question.
Baker‐Smith et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: